Data from Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab

MLA

Benjamin G. Vincent, et al. Data from Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.c.6532436.v1.

APA

Benjamin G. Vincent, Heinz-Josef Lenz, Alan P. Venook, Charles David Blanke, Omar Kabbarah, Monica M. Bertagnolli, Scott Van Buren, Fang-Shu Ou, Xueping Qu, Naim Rashid, Akram Yazdani, & Federico Innocenti. (2023). Data from Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab. https://doi.org/10.1158/1078-0432.c.6532436.v1

Chicago

Benjamin G. Vincent, Heinz-Josef Lenz, Alan P. Venook, Charles David Blanke, Omar Kabbarah, Monica M. Bertagnolli, Scott Van Buren, et al. 2023. “Data from Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab,” March. doi:10.1158/1078-0432.c.6532436.v1.